Whether you’re a weekend DIYer or a pro mechanic, the right car diagnostic tool can save time, money, and frustration. From basic OBD-II code readers to AI-powered remote systems, each option offers ...

From AI-powered fault prediction to real-time sensor monitoring, modern car diagnostics are transforming how we prevent breakdowns. Advanced tools now catch issues early, interpret complex data, and ...

The Studio Display XDR's medical image calibration feature received FDA clearance, which means radiologists are now able to use the display for viewing medical images. Apple marketing chief Greg ...

DELRAY BEACH, Fla., April 2, 2026 /PRNewswire/ -- PanGIA Biotech, Inc. ("PanGIA") announced a peer-reviewed clinical study published in Diagnostics, "Urine-Based Machine Learning Assay Detects ...

AI won’t replace you at work, but someone using AI likely will. Maybe not today or tomorrow. Maybe not this year or even next. But eventually. And if you wait for eventually, it will be too late. For ...

Move over em-dash, there’s a new AI giveaway. It’s hard to deny that AI is everywhere these days, and it’s no surprise that it’s making its way into classrooms. Since sneaky students are figuring out ...

Andy Coravos says offloading tedious tasks to AI has freed her to focus more on the things she loves, like singing and playing guitar. Andy Coravos has a new home helper—named Claude. She assigns her ...

When Jared Hewitt’s co-worker claimed last winter that Hewitt used AI to write an incident report, she did it publicly. “And I work at a day care, so she was berating me in front of children,” he says ...

Enterprise AI spending hit $37 billion in 2025—a 200% jump from the year before. The message from the C-suite couldn’t be clearer: AI is no longer a competitive advantage. It’s table stakes. So why ...

C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation(R), highlighted the first use of its eMTBR-tau243 plasma assay in a Phase 3 dataset ...

C2N Diagnostics Highlights First Use of Its eMTBR-tau243 Plasma Assay in Evoke/Evoke+ Phase 3 Dataset for Prediction of Cognitive and Functional Decline in Patients With Early Symptomatic Alzheimer’s ...